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Pharmacokinetically guided dosing of carboplatin and etoposide during
peritoneal dialysis and haemodialysis
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Summary Two patients with relapsed Wilms' tumour and renal failure requiring dialysis were given
carboplatin and etoposide by pharmacokinetically guided dosing. The target area under the drug plasma
concentration vs time curve (AUC) was 6 mg ml-' min for carboplatin and 18 and 21 mg ml'- min for
etoposide. On course 1 measured AUCs ofcarboplatin and etoposide were 6 and 20 mg ml-' min for patient 1
and 6 and 21 mg ml-l min for patient 2 respectively. Peritoneal dialysis did not remove carboplatin or
etoposide from the plasma, however carboplatin but not etoposide was cleared by haemodialysis. Therapy with
carboplatin and etoposide is possible in children and adults with renal failure who require dialysis, but in this
situation pharmacokinetic monitoring is essential.
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The ability to deliver curative chemotherapy to children with
malignant disease who have hepatic or renal failure poses
major problems. If an anti-cancer agent, or its active
metabolites, is excreted by the kidney, administration in
conventional dosage can cause significant toxicity, so dose
reduction is necessary. In contrast, drugs such as vincristine,
doxorubicin, cyclophosphamide and actinomycin D which
are eliminated by other routes can be given in standard doses
in renal failure. Although drugs which are eliminated by the
kidney without extensive prior metabolism can be adminis-
tered to patients with renal failure by using pharmacokinetic
or therapeutic drug monitoring, the effects of concomitant
peritoneal and haemodialysis must be considered. This report
describes the treatment of two patients with Wilms' tumours,
who had chronic renal failure requiring dialysis, with
carboplatin and etoposide, two drugs which undergo
significant renal clearance.
Case reports
Patient 1 was a 4.3-year-old girl who presented with
haematuria and a rapidly enlarging abdominal mass. A
stage III Wilms' tumour of the left kidney with favourable
histology was removed at laparotomy, but it involved the
abdominal aorta, which ruptured during the operation. The
aorta was repaired but the right kidney had suffered severe
ischaemic damage and she developed renal failure. She was
established on peritoneal dialysis and treated with vincristine,
actinomycin D and doxurubicin for 1 year, but did not
receive radiotherapy. Two months after discontinuing
treatment her tumour recurred with the development of loin
pain, blood staining ofher dialysis fluid and a mass involving
para-aortic lymph nodes in her left renal bed.
Patient 2 was a 17-year-old male who was found to have a
left-sided abdominal mass and iron deficiency anaemia at a
routine medical examination. At the age of 2 he had been
treated for a right-sided Wilms' tumour (stage I, favourable
histology) with nephrectomy, radiotherapy and vincristine for
1 year. At relapse the mass was confirmed to be a
metachronous Wilms' tumour with favourable histology,
after percutaneous biopsy. There were no metastases
demonstrated elsewhere. He received chemotherapy with
vincristine, actinomycin D and doxorubicin, but after 10
weeks a computerised axial tomographic scan showed
progression of his disease. A right-sided nephrectomy was
performed and haemodialysis was commenced. There was
macroscopic complete excision but three lymph nodes were
replaced by tumour.
Alternative chemotherapy was required because both
patients had relapsed or resistant disease. Ifosfamide,
etoposide and carboplatin have all shown single-agent
activity against Wilms' tumour in phase II trials (de
Camargo et al., 1994; Ettinger et al., 1994; Pein et al.,
1993; Pinkerton et al., 1985), but ifosfamide may cause severe
encephalopathy when given to patients with renal failure
(Mermimsky et al., 1992). The combination of carboplatin
and etoposide represented the most active combination of
drugs not already used in these patients (Pein et al., 1994).
Pharmacokinetic monitoring with adaptive control of
dosing by feedback, rather than conventional dosing
according to body weight or surface area, was used to
achieve a target area under the drug plasma concentration
against time curve (AUC) in both patients, because the
pharmacokinetics of both carboplatin and etoposide is
markedly affected by renal function.
Methods
Calculation of target AUC values
For each drug the AUC associated with the administration of
a standard dose to patients with normal renal function was
calculated. For carboplatin a dose of 450 mg m-2 was
chosen, for which the median AUC would be approximately
6 mg ml-' min (Newell et al., 1993). AUC-based dosing of
children with etoposide had not been reported at the time
these patients were treated, and target AUCs were chosen
based upon a large number of previous studies in this centre
(Lowis et al., 1993). For patient 1 an etoposide dose aimed to
give the same mean AUC as a dose of 450 mg m-2 was
chosen, and for patient 2 this was raised to 500 mg m-2. In
patients with normal renal function these doses would be
expected to give mean AUCs of 18 and 21 mg ml-' min
respectively for one cycle of therapy.
Carboplatin was administered as a 60 min infusion to
patients on days 1 and 3 ofchemotherapy. The dose on day 1
was calculated assuming a GFR of zero aiming for a target
AUC of 6 mg ml-' min using the formula:
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Dose (mg) = target AUC ( mg ml-' min) x
[GFR (ml min-')+ (0.36 x BW (kg))]
where BW equals the body weight (Newell et al., 1993). The
dose for day 3 was calculated after the AUC following the
initial dose had been measured, with the aim of achieving a
total AUC of 6 mg ml-' min when both doses were
combined. Etoposide was given as a 3 h infusion on 3
consecutive days. The initial dose of etoposide for each
patient was chosen assuming that all clearance would be non-
renal and hence in both patients approximately 50% of the
conventional dose was given (D'Incalci et al., 1986).
Measurements of etoposide plasma concentrations were
performed after each dose and the amount given on the
next day was altered based on these results. Patient 1 had
dialysis performed at the same time after treatment on each
day. It was intended to dialyse patient 2 24 h after his
chemotherapy, but he developed life-threatening hyperkalae-
mia and dialysis had to be brought forward to 10 h post
chemotherapy. This time interval between the end of drug
administration and subsequent dialysis was maintained for
subsequent doses and courses.
Pharmacokinetic sampling and analysis
Total and free carboplatin and total etoposide concentrations
were determined in patient plasma samples. Fourteen (patient
1) and 22 (patient 2) samples were taken after each dose. For
carboplatin 3 ml of whole blood and for etoposide 2 ml were
collected into lithium heparin tubes and the plasma separated
by centrifugation. Free platinum was separated from 1 ml
aliquots of plasma by centrifugal ultrafiltration as described
previously (Harland et al., 1984) and all specimens were
stored at -20°C until analysis. Determination of total and
free platinum concentrations was by atomic absorption
spectrophotometry (Harland et al., 1984). Total plasma
etoposide concentrations were measured by high perfor-
mance liquid chromatography (Newell et al., 1989).
Samples of peritoneal dialysis fluid and urine were
obtained from patient 1 whenever possible, but only blood
samples were collected from patient 2, who was anephric. All
blood samples from patient 1 were taken from a central
venous line. Samples from patient 2 were either taken from a
peripheral cannula or from the afferent lumen of his dialysis
catheter. Simultaneous samples were also obtained from the
afferent and efferent lumens of his dialysis catheter 670 min
after completion of his carboplatin infusion. These samples
were assayed for ultrafilterable platinum as above. No
samples were collected from peripheral or central venous
sites where carboplatin or etoposide had been administered.
Initial calculations of the AUC of etoposide were made
using the trapezoidal method with extrapolation to inifinity,
and these values were used to calculate subsequent doses. For
determination of the actual AUC over the entire course of
chemotherapy, simultaneous fitting of all data to a two-
compartment model was performed using ADAPT II
software, release 3 (D'Argenio and Schumitzky, 1979). The
AUC of ultrafilterable platinum was determined by the
trapezoidal rule with extrapolation to infinity. In addition,
for patient 2, a pharmacokinetic model was fitted to the
carboplatin data using ADAPT II. The model used consisted
of two compartments with elimination from the central
compartment. Elimination was characterised by a constant
clearance (Cl) and, during the period of haemodialysis, a
parallel clearance due to haemodialysis (Clh). Both clear-
ances were estimated as parameters of the model with an
indicator variable included to signal the beginning and end of
haemodialysis. Since peritoneal dialysis did not affect the
pharmacokinetics of carboplatin, the model was not applied
to data from patient 1.
Haematological toxicity
Toxicity was coded according to common toxicity criteria.
The total white cell count, absolute neutrophil count (ANC)
and platelet count were determined every 2-3 days at the
time patients attended for dialysis. Toxicity from anaemia in
these patients has not been considered separately because of
the additional influence of chronic renal failure.
Results
Pharmacokinetic data for the first cycle of carboplatin and
etoposide in patient 1 and for three out of six cycles in
patient 2 are given in Table I. The dose on day 1 was given
based on the assumption of no renal function and subsequent
doses were modified on the basis of the results of the
pharmacokinetic analyses. On course 1 in both patients the
total target AUCs during the course were achieved with a
high degree of accuracy: measured AUCs of 6 and
21 mg ml-' min for carboplatin and etoposide against target
AUCs of 6 and 18 mg ml-' min for patient 1; and measured
AUCs of 6 and 20 mg ml-1 min against target AUCs of 6
and 21 mg ml-' min for patient 2 respectively. The dose of
carboplatin was reduced by 25% after course 1 for patient 2
because of haematological toxicity. A smaller etoposide dose
was given on course 4 because of reduced clearance. As can
be seen, carboplatin was cleared by haemodialysis but
etoposide was not, and neither drug was cleared by
peritoneal dialysis.
Pharmacokinetic profiles for the first cycles of carboplatin
and etoposide in both patients are shown in Figures 1-4.
Patient 1 had some residual renal function with a 51Cr EDTA
clearance of 2 ml min-' (5.2 ml min-' 1.73 m-2). Consistent
with the residual renal function in this patient, the urinary
elimination of carboplatin and etoposide accounted for 30%
and 6% of the administered doses, respectively. The plasma
clearance of carboplatin was 5 ml min-1 (carboplatin and
5"Cr EDTA were administered simultaneously).
Patient 2 required early haemodialysis 10 h after the initial
dose of carboplatin had been given because of hyperkalae-
mia. Haemodialysis, applied 10 h after the dose of
carboplatin, increased the total clearance of free drug such
that an AUC of only 2.7 mg ml-1 min was achieved. If no
haemodialysis was applied the projected AUC following this
dose would have been 4 mg ml-' min. When the dose was
repeated on day 3, with dialysis applied at the same time after
the carboplatin dose and for the same duration, the AUC
was 3.3 mg ml-1 min. Thus, by monitoring the pharmacoki-
netics of free carboplatin and applying haemodialysis in a
consistent manner we were able to achieve the target AUC of
6 mg ml-' min.
Table I Pharmacokinetic parameters for carboplatin and etoposide
using a two-compartment model
Patient I Patient 2
Course 1 2 3 1 2 4
Carboplatin
Total AUC 6.0 a a 6.0 5.2 4.6
(mg ml-' min)
Total dose
(mgm-2) 106 106 106 274 213 213
Clearance see
(ml min-'m-2) 17 a a Table II
Etoposide
Total AUC
(mg ml min'-) 21 a a 20 19 23
Total dose
(mg m 2) 358 358 358 402 433 328
Clearance
(ml min-'m-2) 17 a a 20 23 14
Volume of
distribution (lm 2) 8 a a 11 12 13
Half-life a 125 a a 163 88 125
Half-life fi 619 a a 568 489 891
a Not measured
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Figure 2 Plasma concentrations of free carboplatin in patient 2
on haemodialysis.-, Model; E], data.
For patient 2 the model of ultrafilterable platinum
pharmacokinetics with haemodialysis provided a good fit to
the data (Figure 2), including a rebound increase in
concentration at the end of haemodialysis. This is
presumably due to redistribution of carboplatin from the
peripheral to the central compartment following the cessation
of the rapid elimination from the central compartment. The
parameter values obtained from the three cycles of
carboplatin studied in patient 2 are given in Table II. The
clearance due to haemodialysis approaches the plasma flow
through the haemodialysis apparatus of 140 ml min-' (blood
flow =200 ml min-', haematocrit of 28%). This value is also
similar to that obtained in a previous study (Chatelut et al.,
1994). The percentage of free carboplatin extracted during
one passage through the haemodialysis apparatus was 61%
(comparing afferent and efferent ultrafilterable platinum
concentrations), again indicating efficient clearance by
haemodialysis when corrected for haematocrit.
Toxicity
Table III shows the haematological and infectious complica-
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Figure 4 Plasma concentrations of etoposide in patient 2 on
haemodialysis.
thrombocytopenia and neutropenia. There were no treatment
delays for patient 1, but patient 2 had his second course of
treatment modified because of neutropenia and thrombocy-
topenia.
Nausea and vomiting was grade 3 in patient 1 and grade 4
in patient 2. Interestingly, his symptoms of nausea and
vomiting would resolve with dialysis.
Outcome
After three courses of treatment, patient 1 achieved a partial
response following which macroscopic surgical removal of a
largely necrotic tumour was possible. Therapy was completed
with radiotherapy to the tumour bed with 32 Gy in 18
fractions. She relapsed 1 month after treatment finished and
has since died.
Response was not evaluable in patient 2 because there was
no residual disease. He received local radiotherapy to the
tumour bed and 5 courses of chemotherapy. He remains
disease-free 7 months after completing treatment.
This report describes combined, targeted dosing of carbopla-
tin and etoposide in a child and a young adult patient on
Table II Model-dependent pharmacokinetic parameters for carboplatin from three courses of treatment for patient 2
Course Cl (ml min-') V (1) Clh (ml min-') K]2(min-') K2V(min-1)
1 18.5 19 130 0.0011 0.0014
2 29.7 11 88 0.0154 0.0153
4 20.7 10 139 0.0112 0.0094
The model contains two routes ofelimination. One is constant (Cl) and corresponds to the non-renal elimination ofcarboplatin. The other is
discontinuous (Clh) andisdue tohaemodialysis. V, volumeofcompartment 1. K12andK2, arethefirst-order rateconstantsfordistribution between
compartments 1 and 2.
t 1% ) IX "Carboplatin, etoposide and dialysis
MW English et al
dialysis. It is possible to achieve target AUCs for both drugs
using pharmacokinetic monitoring so that effective drug
levels are reached with acceptable toxicity.
Although previous reports have monitored the pharmaco-
kinetics of carboplatin in renal failure (Koren et al., 1993;
Motzer et al., 1990) there has been only one report of
targeted dosing of carboplatin (to an AUC of
6 mg ml-1 min) in a patient with ovarian carcinoma and
renal failure (Chatelut et al., 1994). In the patients reported
in this present study carboplatin was not cleared from plasma
by peritoneal dialysis but was cleared by haemodialysis,
confirming previous studies (Hall et al., 1994; Koren et al.,
1993; Motzer et al., 1990).
Patients who have residual renal function will be under-
dosed by the dosing formula used here if it is assumed that
their GFR is zero. The complete formula takes account of
both renal and non-renal clearance (Newell et al., 1993) and
is currently being validated in children with normal renal
function in a United Kingdom Children's Cancer Study
Group (UKCCSG) study. The paediatric dosing fomula has
not undergone prospective evaluation in the situation of such
severe renal impairment, so pharmacokinetic studies are
recommended to measure the actual carboplatin AUC in
similar patients in the future.
Koren et al. (1993) performed haemodialysis 12-18 h
after administration of carboplatin and other authors have
carried out dialysis 24 h after carboplatin (Chatelut et al.,
1994; Hall et al., 1994; Koren et al., 1993; Motzer et al.,
1990). It was intended to wait 24 h before patient 2 was
dialysed and his dose ofcarboplatin was calculated to give an
AUC of 6 mg ml-' min assuming no effect from dialysis.
Despite good dietary control hyperkalaemia developed soon
after the start of chemotherapy and dialysis was necessary
10 h after the completion of the first dose of carboplatin,
resulting in an AUC of only 2.7 mg ml-1 min. However,
pharmacokinetic monitoring made it possible to give an
additional dose of carboplatin to achieve the intended AUC.
Cisplatin has also been used to treat patients with renal
failure on haemodialysis (Fox et al., 1991; Ribrag et al.,
1993; Tanabe et al., 1994). Fox et al. and Ribrag et al.
administered test doses of cisplatin during haemodialysis
(Fox et al., 1991; Ribrag et al., 1993). Tanabe et al.
administered cisplatin immeiately before dialysis in three
divided doses and carried out a pharmacokinetic analysis of
the first course (Tanabe et al., 1994). The active agent for
both cisplatin and carboplatin is the free platinum drug that
is hydrolysed before it binds to DNA or protein. Cisplatin is
hydrolysed 10-20 times faster than carboplatin and the
main route of clearance of free cisplatin is by binding to
macromolecules. In spite of this, when renal function
deteriorates the plasma clearance of free platinum drops
(Reece et al., 1986), and in one anephric patient the plasma
clearance of free platinum was five times lower than in
individuals with normal renal function (Tanabe et al., 1994).
Thus, adaptive control of cisplatin can be used in patients
with renal failure. Cisplatin has been shown to be active
against relapsed Wilms' tumour in a few cases (Marina et
al., 1994), however carboplatin was chosen in the present
study because there are more phase II studies demonstrating
its activity against Wilms' tumour (de Camargo et al., 1994;
Ettinger et al., 1994) and there was more experience with
targeted dosing of carboplatin in children (Marina et al.,
1993; Newell et al., 1993) and adults (Calvert et al., 1989).
Etoposide is normally eliminated by renal (60%) and
hepatic (40%) mechanisms (Joel et al., 1994). Renal
impairment is predictive of toxicity in patients receiving
etoposide (Clark et al., 1988), and a dose reduction of 50%
has been suggested in all patients with poor kidney function
(D'Incalci et al., 1986). This approach in patient 1 would have
given a similar exposure to that seen with pharmacokinetically
guided dosing, since etoposide clearance was approximately
60% of normal. However, patient 2 had a clearance that was
77% of the median from our previously reported data in an
unselected patient population, despite a complete absence of
renal function (Lowis et al., 1993). Dose reduction by 50% in
this patient would have led to significant underexposure. A
number of studies have demonstrated the importance of
pharmacokinetic variability in determining responses for the
epipodophyllotoxins (Miller et al., 1992; Rodman et al., 1987),
and there are severe potential consequences of both under-
dosing and overdosing. The observation that etoposide was
not cleared by haemodialysis or peritoneal dialysis is
important and confirms both in vitro (Sauer et al., 1990) and
in vivo observations (Holthuis et al., 1985). Etoposide is highly
protein bound and the small amounts of unbound etoposide
cleared by haemodialysis would not be sufficient to alter total
plasma levels. The repeated studies performed on patient 2
showed marked variability in plasma clearance, and, in
particular, this appears to be due to variability in the terminal
phase elimination half-life. The volume of distribution of
etoposide increased in the final study, whereas t112p rose from
489 to 891 min. Dialysis was begun at approximately the same
time on each occasion, and in any case did not contribute
significantly to the plasma clearance of etoposide. It is
therefore difficult to explain why such a large variation
should occur.
Both the patients reported here developed grade 3-4
thrombocytopenia and neutropenia which suggests that
patient exposure was at near limiting levels. These findings
are consistent with a phase II study of carboplatin and
etoposide in patients with relapsed or refractory Wilms'
tumour who received doses of 750 mg m-2 carboplatin and
500 mg m-2 etoposide over 5 days where considerable
haematological toxicity with grade 4 thrombocytopenia was
observed in all 25 evaluable patients (Pein et al., 1994). A
small increase in carboplatin dose resulted in considerably
Table HI Haematological toxicity and infections after all courses of treatment
Patient 1 Patient 2
Course 1 2 3 1 2 3 4 5 6
Nadir neutrophil
count 0.8 0 2.5 0.2 0.3 0.1 0.2 0.2 0.4
(X 109 1-1)
Number of days
neutrophils <1.0 5 9 0 5 2 8 15 4 15
x 109 11
Nadir platelet
count 106 18 128 27 51 26 30 23 18
(X 109 i-1)
Number of days
platelets < 0 3 0 4 0 3 3 4 3
50x 109 I-
Infections a No No No No No No b No
aStaphylococcal central venous line infection. bMinor infection at central venous catheter exit site.
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increased toxicity in an anephric patient reported by Koren et
al. (1993) which underlines the importance of identifying a
target AUC and then monitoring the achieved AUC.
In conclusion, treatment with carboplatin and etoposide is
possible in patients with renal failure who require dialysis,
however in this situation pharmacokinetic monitoring is
essential. Timing of the peritoneal dialysis or haemodialysis
relative to the administration of etoposide is not important.
However the timing of haemodialysis, but not peritoneal
dialysis, has a critical effect on the AUC of carboplatin.
Further studies are required to define the optimum AUCs of
carboplatin and etoposide required to achieve a response with
acceptable toxicity in paediatric tumours. Until such studies
are performed, targeted dosing of carboplatin to an AUC of
6 mg ml-' min and etoposide to a total AUC of 21 mg ml-I
min is recommended as a schedule that produces significant,
but manageable toxicity.
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